home / stock / dbvt / dbvt news


DBVT News and Press, DBV Technologies S.A. From 05/02/24

Stock Information

Company Name: DBV Technologies S.A.
Stock Symbol: DBVT
Market: NASDAQ
Website: dbvtechnologies.com

Menu

DBVT DBVT Quote DBVT Short DBVT News DBVT Articles DBVT Message Board
Get DBVT Alerts

News, Short Squeeze, Breakout and More Instantly...

DBVT - Expected US Company Earnings on Thursday, May 2nd, 2024

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

DBVT - Combined General Meeting of May 16, 2024

Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a cl...

DBVT - Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...

DBVT - DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused...

DBVT - DBV Technologies S.A. (DBVT) Q4 2023 Earnings Call Transcript

2024-03-07 21:58:08 ET DBV Technologies S.A. (DBVT) Q4 2023 Earnings Conference Call March 07, 2024 05:00 PM ET Company Participants Katie Matthews - Investor Relations Daniel Tassé - Chief Executive Officer Pharis Mohideen - Chief Medical Officer Virgin...

DBVT - DBV Technologies GAAP EPS of -$0.76, revenue of $15.7M

2024-03-07 17:18:53 ET More on DBV Technologies Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for DBV Technologies Read the full article on Seeking Alpha For further details...

DBVT - DBV Technologies Reports Full Year 2023 Financial Results and Business Update

Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) Strengthened exec...

DBVT - Expected US Company Earnings on Thursday, March 7th, 2024

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

DBVT - DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on trea...

DBVT - DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced...

Previous 10 Next 10